Jiangsu Kanion Pharmaceutical Co., Ltd.

To explore the effectiveness and safety of Xingbei cough-relieving granules in treating post-infectious cough (wind-heat attacking the lung syndrome)

1. To preliminarily evaluate the clinical efficacy and safety of Zaobai Anshen Granules in the treatment of insomnia (liver blood deficiency, internal disturbance of deficiency heat syndrome). 2. To explore the clinical dose-effect relationship of Zaobai Anshen Granules in the treatment of insomnia (liver blood deficiency, internal disturbance of deficiency heat syndrome), and provide a basis for the selection of the dosage for Phase III clinical trials.

The study used healthy subjects as the test subjects and adopted a randomized, open, two-period, two-sequence, double-crossover design to investigate the in vivo time course of linagliptin after a single oral administration of linagliptin tablets (test preparation, specification: 5 mg) produced by Jiangsu Kangyuan Pharmaceutical Co., Ltd. and linagliptin tablets (reference preparation, trade name: Trajenta®, specification: 5 mg) produced by West-Ward Columbus Inc. (certified by Boehringer Ingelheim International GmbH) to estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in fasting and postprandial states, and provide a basis for the production registration application of the test preparation.